{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049235","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.059750+00:00","generated_at":"2026-05-17T00:18:39.760479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arvinas Q3 cash $787.6M; vepdegestrant NDA accepted PDUFA June 2026","bullets":["Cash and securities $787.6M at Sept 30, 2025, down from $1,039.4M at Dec 31, 2024; cash runway into H2 2028.","R&D expenses $64.7M in Q3 2025 vs $86.9M in Q3 2024, down 26% YoY due to lower program costs.","FDA accepted NDA for vepdegestrant in ER+/HER2- breast cancer; PDUFA date June 5, 2026.","ARV-102 Phase 1 showed >90% LRRK2 reduction in PBMCs; no SAEs; multiple dose cohort launched in Parkinson's.","Repurchased $17.8M of common shares under stock repurchase program in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049235","json":"https://secwatch.observer/filing/0001628280-25-049235.json","markdown":"https://secwatch.observer/filing/0001628280-25-049235.md","text":"https://secwatch.observer/filing/0001628280-25-049235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/0001628280-25-049235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/arvn-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:18:39.760479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}